Your source of breaking information about Dutasteride also known as Avodart, Avolve, GI198745, GG745 or Duagen.
dutasteride duagen avodart avolve 
  Dutasteride.org is an independent clearinghouse for information about Dutasteride and is not associated or affiliated with GlaxoSmithKline or the Glaxo Group Limited. Avolve, Avodart and Duagen are registered trademarks of Glaxo Group Limited.  


What is Dutasteride

The Latest News

Dutasteride Studies

Dutasteride Safety Profile

FDA Approval Documents

Dutasteride Results


If you are interested in getting more information via email about the availability of Avodart please enter your email address below

hair loss MPB Dutasteridedutastiride avolve duagen
 
Dutasteride Research Studies
 
Publication: Clin Pharmacol Ther 1998 Dec;64(6):636-47
Authors: Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO.
Institution: Division of Clinical Pharmacology, GlaxoWellcome Research and Development, Middlesex, England. po7205
 
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
 

OBJECTIVE: To develop a pharmacokinetic-pharmacodynamic model that characterizes the conversion of testosterone to dihydrotestosterone (DHT) by 5 alpha-reductase types 1 and 2 and the irreversible inhibition of 5 alpha-reductase by finasteride, a 5 alpha-reductase type 2 inhibitor and by GI198745 (dutasteride), a potent and specific dual 5 alpha-reductase inhibitor.

METHODS: Healthy men (n = 48) received doses of 0.1 to 40 mg GI198745 (n = 4 subjects per dose), 5 mg finasteride (n = 8), or placebo (n = 8) in a parallel-group study. Plasma concentrations of GI198745, finasteride, and DHT were measured frequently up to 8 weeks after dosing. Models were fitted with mixed-effects modeling with the NONMEM program.

RESULTS: The pharmacodynamics were well described with a model that accounted for the rates of DHT formation and elimination, 5 alpha-reductase turnover, relative capacity of the 2 5 alpha-reductase isozymes, and the rates of irreversible inhibition of one (finasteride) or both (GI198745) types of 5 alpha-reductase. The model indicated that type 2 5 alpha-reductase contributed approximately 80% of plasma DHT. GI198745 was about 3-fold more potent than finasteride on 5 alpha-reductase type 2. Nearly full blockade of both isozymes was achieved at doses of 10 mg or more GI198745, although the potency of this agent on 5 alpha-reductase type 1 was less than on type 2.

CONCLUSIONS: A physiologically based model for the turnover and irreversible inhibition of 5 alpha-reductase and for formation and elimination of DHT described the data well. This model helps explain differences in the rates of onset and offset of effect and offers a way to determine the relative potency of the irreversible 5 alpha-reductase inhibitors.

Publication Types:

  • Clinical Trial
  • Randomized Controlled Trial
 
lowers DHT and promotes hair regrowth
Glaxo sells Avodart also know as Dutasteride   Avolve Avodart  GI198745  Duagen
 
  Copyright © 2002 Interactive Marketing Group - All Rights Reserved - email: info@dutasteride.org